Robert A Fenstermaker1, Michael J Ciesielski. 1. Department of Neurosurgery, Roswell Park Cancer Institute, Buffalo, NY 14263, USA. robert.fenstermaker@roswellpark.org
Abstract
BACKGROUND: Despite advances in surgery, radiation therapy, and chemotherapy, only modest improvement has been achieved in the survival of patients with malignant gliomas. METHODS: The authors review the immunologic aspects of gliomas, potential targets for therapy, and issues surrounding current immunotherapeutic strategies directed against malignant gliomas. RESULTS: The blood-brain barrier and the purported immunological privilege of the brain are not necessarily insurmountable obstacles to effective immunotherapy for brain tumors. Preclinical studies suggest a number of potential therapeutic avenues. Translational studies offer the prospect of providing substantial new information about immunological trafficking in the nervous system and suggesting the most fruitful approaches to immunotherapy for malignant gliomas. CONCLUSIONS: More effective adjuvant treatments for malignant gliomas are needed. The applicability of immunological approaches in the treatment of these tumors warrants continued study.
BACKGROUND: Despite advances in surgery, radiation therapy, and chemotherapy, only modest improvement has been achieved in the survival of patients with malignant gliomas. METHODS: The authors review the immunologic aspects of gliomas, potential targets for therapy, and issues surrounding current immunotherapeutic strategies directed against malignant gliomas. RESULTS: The blood-brain barrier and the purported immunological privilege of the brain are not necessarily insurmountable obstacles to effective immunotherapy for brain tumors. Preclinical studies suggest a number of potential therapeutic avenues. Translational studies offer the prospect of providing substantial new information about immunological trafficking in the nervous system and suggesting the most fruitful approaches to immunotherapy for malignant gliomas. CONCLUSIONS: More effective adjuvant treatments for malignant gliomas are needed. The applicability of immunological approaches in the treatment of these tumors warrants continued study.
Authors: Michael J Ciesielski; Danuta Kozbor; Carla A Castanaro; Tara A Barone; Robert A Fenstermaker Journal: Cancer Immunol Immunother Date: 2008-04-26 Impact factor: 6.968
Authors: Carlos E A Batista; Csaba Juhász; Otto Muzik; William J Kupsky; Geoffrey Barger; Harry T Chugani; Sandeep Mittal; Sandeep Sood; Pulak K Chakraborty; Diane C Chugani Journal: Mol Imaging Biol Date: 2009-05-12 Impact factor: 3.488
Authors: Fabio Grizzi; Paolo Gaetani; Barbara Franceschini; Antonio Di Ieva; Piergiuseppe Colombo; Giorgia Ceva-Grimaldi; Angelo Bollati; Eldo E Frezza; E Cobos; Riccardo Rodriguez y Baena; Nicola Dioguardi; Maurizio Chiriva-Internati Journal: BMC Cancer Date: 2006-01-26 Impact factor: 4.430
Authors: Mario Orozco-Morales; Francisco Javier Sánchez-García; Irene Golán-Cancela; Norma Hernández-Pedro; Jose A Costoya; Verónica Pérez de la Cruz; Sergio Moreno-Jiménez; Julio Sotelo; Benjamín Pineda Journal: Cancer Cell Int Date: 2015-06-05 Impact factor: 5.722
Authors: Supreet Agarwal; Maha S Al-Keilani; Mohammad A Y Alqudah; Zita A Sibenaller; Timothy C Ryken; Mahfoud Assem Journal: PLoS One Date: 2013-05-16 Impact factor: 3.240
Authors: Q F Sun; X N Zhao; C L Peng; Y T Hao; Y P Zhao; N Jiang; H Xue; J Z Guo; C H Yun; B Cong; X G Zhao Journal: Oncol Rep Date: 2015-08-27 Impact factor: 3.906
Authors: Suhela Kapoor; V P Subramanyam Rallabandi; Chandrashekhar Sakode; Radhakant Padhi; Prasun K Roy Journal: Theor Biol Med Model Date: 2013-12-26 Impact factor: 2.432
Authors: Se Jeong Lee; Won Young Kang; Yeup Yoon; Ju Youn Jin; Hye Jin Song; Jung Hyun Her; Sang Mi Kang; Yu Kyeong Hwang; Kyeong Jin Kang; Kyeung Min Joo; Do-Hyun Nam Journal: BMC Cancer Date: 2015-12-24 Impact factor: 4.430